Concepedia

Synthesis and antitumor evaluation of 5-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(tert-butyl)-N-arylthiazol-2-amines

Zhensen Wu, Yilin Fang, Yani Tang, Mengwu Xiao, Jingfeng Ye, G. X. Li, Ai‐Xi Hu

MedChemComm · 2016 · 14 citations · 27 references

DOI

Concepts

Abstract

The strategy for designing target compounds as antitumor agents.

References

27

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations

, , +11

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text

, , +17

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock et al. · The Lancet · 2012 · 933 citations · Full text

, , +12

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes et al. · Blood · 2011 · 605 citations · Full text

, , +8

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Elias Jabbour, Hagop M. Kantarjian, Giuseppe Saglio et al. · Blood · 2013 · 391 citations · Full text

, , +8